Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Glutamate receptor ionotropic, NMDA 2C is a specific subunit of the N-methyl-D-aspartate (NMDA) receptor complex, which functions as a ligand-gated cation channel essential for excitatory signaling in the central nervous system [1, 2]. Predominantly expressed in the cerebellum, olfactory bulb, and thalamus, this subunit forms heteromeric complexes with GluN1 that exhibit unique biophysical characteristics, such as a weaker voltage-dependent magnesium block and lower single-channel conductance compared to other NMDA subtypes [2]. These properties allow the receptor to modulate neuronal excitability and contribute significantly to tonic excitatory currents and synaptic plasticity, particularly in motor and sensory circuits [2, 3]. Genetic variations or functional imbalances in this molecule are linked to several neuropsychiatric and neurological conditions, including schizophrenia, epilepsy, and movement disorders [1, 4]. While established therapeutics like memantine target NMDA receptors broadly, this specific subunit is a focus for the development of selective allosteric modulators intended to treat cognitive and motor deficits with high precision [4, 5]. Research tools like CIQ and DQP-1105 have been instrumental in defining the therapeutic potential of modulating this receptor in isolation from its more widely distributed counterparts [3, 5].
Drugs targeting the GluN2C-containing NMDA receptors typically function as either uncompetitive channel blockers, which obstruct the ion pore during activation to prevent cation influx, or as allosteric modulators that bind to specific domains to either potentiate (positive allosteric modulators) or reduce (negative allosteric modulators) the channel's response to the endogenous agonists glutamate and glycine [2, 5]. Some compounds specifically target the glycine-binding site to modulate the receptor's sensitivity and gating kinetics [3, 4].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate receptor ionotropic, NMDA 2C (GluN2C).